Fulcrum therapeutics® reports inducement grants under nasdaq listing rule 5635(c)(4)

Cambridge, mass., nov. 11, 2022 (globe newswire) -- fulcrum therapeutics, inc. (nasdaq: fulc), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to new employees as inducement awards outside of the company's 2019 stock incentive plan.
FULC Ratings Summary
FULC Quant Ranking